Aldeyra dry eye disease candidate hit by FDA delay amid shifting agency guidance, biotech says
Aldeyra dry eye disease candidate hit by FDA delay amid shifting agency guidance, biotech says
본문을 이용할 수 없습니다. 원본 출처를 확인하세요.
Aldeyra dry eye disease candidate hit by FDA delay amid shifting agency guidance, biotech says
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.